Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs NKTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NKTX Captures Overall Composite Edge (50.5 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars
NKTX Overall Winner
6-Pillar Tally: FDMT 3 – 2 NKTX (1 Tie)
Matrix Metrics: FDMT 5 – 3 NKTX
As of Nov 16, 2026, Nkarta, Inc. (NKTX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.5/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus NKTX at $1.21 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NKTX 50.5/100 HOLD), NKTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY).
- Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile NKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FDMT vs NKTX
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$11.65
-4.74% 1D
Market Cap
$669.3M
TTM Revenue
$96M
Forward P/E
N/M
Beta / 30D Vol
1.89β · 90% Vol
Unified Composite Score
51.3
HOLD
Tech 51.0
Fund 47.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
NKTX
Head-to-Head Winner
Nkarta, Inc. Common Stock
$1.21
+1.26% 1D
Market Cap
$90.6M
TTM Revenue
$385
Forward P/E
N/M
Beta / 30D Vol
1.89β · 117% Vol
Unified Composite Score
50.5
HOLD
Tech 43.0
Fund 59.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 NKTX)
1. Valuation Multiples
FDMT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.6x
N/M
2. Growth & Scale
FDMT
Revenue Growth (YoY)
+4505.6%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$96M
$385
Market Cap
$669.3M
$90.6M
3. Profitability & Quality
NKTX
Gross Margin
N/A
N/A
Operating Margin
-222.7%
0.0%
Net Profit Margin
-208.6%
0.0%
Return on Equity (ROE)
-56.7%
-46.6%
4. Balance Sheet & Cash Flow
FDMT
Cash Generation (TTM)
-$156M
-$94M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$31M Net Cash
$49M Net Debt (0.30x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NKTX
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
82.4% (10th %ile)
0.0% (<1st %ile)
Put/Call OI Skew
5.16x (Put-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FDMT (5) vs NKTX (3)| Institutional Metric | FDMT | NKTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $669.3M | $90.6M | FDMT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +4505.6% | +0.0% | FDMT | |
| Operating Margin (TTM) | -222.7% | 0.0% | NKTX | |
| Net Profit Margin | -208.6% | 0.0% | NKTX | |
| Return on Equity (ROE) | -56.7% | -46.6% | NKTX | |
| 52-Week Range Position | 47% ($7–$17) | 4% ($1–$4) | FDMT | |
| Beta / 30D Volatility | 1.89β · 90% Vol | 1.89β · 117% Vol | FDMT | |
| Unified Institutional Score | 51.3 / 100 (HOLD) | 50.5 / 100 (HOLD) | FDMT | |
| Trailing 12M Revenue (USD) | $96M | $385 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$156M ($31M Net Cash) | -$94M ($49M Net Debt (0.30x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FDMT +29.02 pp
3M Horizon
FDMT +29.14 pp
6M Horizon
FDMT +94.31 pp
1Y Horizon
FDMT +49.23 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | NKTX Revenue | FDMT Op. Margin | NKTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -729.4% | -19433.9% | FDMT |
| FY2020 | $10M | N/A | -424.0% | N/A | FDMT |
| FY2021 | $20M | N/A | -395.5% | N/A | FDMT |
| FY2022 | $0M | N/A | -3516.5% | N/A | FDMT |
| FY2023 | $20M | N/A | -544.6% | N/A | FDMT |
| FY2024 | $0M | N/A | -507678.4% | N/A | FDMT |
| FY2025 | $90M | N/A | -187.2% | N/A | FDMT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FDMT
BREAKDOWN
Current IV
82.4%
IV Percentile
10th %ile
Put/Call OI Skew
5.16x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NKTX
UNCLASSIFIED
Current IV
0.0%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact NKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FDMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NKTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FDMT vs NKTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Nkarta, Inc. (NKTX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.5/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus NKTX at $1.21 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NKTX 50.5/100 HOLD), NKTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile NKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with NKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $385 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while NKTX shifted N/A. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NKTX.
FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas NKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus NKTX (-46.6% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, NKTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.89β · 117% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NKTX vs FDMT · Reverse Pair
FDMT vs STOK
· Sector Peer
FDMT vs ANNX
· Sector Peer
FDMT vs CGEM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking